Effectiveness of Qualia NAD+ Supplementation on NAD Levels

NCT06812416 | Completed

• 1 other identifier: NHC-003
• Study Type: interventional
• Target: 92
• Locations: 1 country
• Sites: 1

Brief Summary

The current study is designed as a randomized double-blind placebo-controlled parallel trial. It aims to investigate the efficacy of Qualia NAD+ on intracellular NAD levels in blood samples (primary outcomes) and health-related quality of life (secondary outcomes) in an adult population experiencing moderate to severe joint pain between ages of 40 and 65 years.

Conditions

Intracellular NAD+ Levels

Keywords

NAD

Outcome Measures

Primary Outcomes (1)

• Intracellular NAD+ Levels

  Baseline and day 28

Secondary Outcomes (2)

• Aging Male/Female Symptom scale

  Baseline, day 14, and day 28

• RAND SF-36

  Baseline, day 14, and day 28

Study Arms (2)

Qualia NAD+

ACTIVE COMPARATOR

Qualia NAD+

Dietary Supplement: Qualia NAD+

Placebo

PLACEBO COMPARATOR

Rice Flour Placebo

Dietary Supplement: Rice Flour Placebo

Interventions

Qualia NAD+ DIETARY_SUPPLEMENT

Qualia NAD+

Qualia NAD+

Rice Flour Placebo DIETARY_SUPPLEMENT

Rice Flour Placebo

Placebo

Eligibility Criteria

• Age: 40 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text.
• Healthy male and female participants between the ages of 40-65 years of age. Willingness to complete questionnaires, records, and diaries associated with the study.
• Willing to not consume any supplements, energy drinks/shots, or other products containing any form of supplemental vitamin B3 (e.g., niacin, niacinamide, nicotinamide ribosome, NMN) starting about 2 weeks prior to the baseline NAD fingerstick test and continuing through the intervention period.
• Willing to not begin taking any new supplements during the study period, and to continue taking any supplements they are currently using regularly (with the exception of vitamin B3 containing supplements).
• Willing to self-administer the intracellular NAD fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests.

You may not qualify if:

• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent

Sponsors & Collaborators

• Qualia Life Sciences: lead

Study Sites (1)

Remote Study

Carlsbad, California, 92011, United States

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 2, 2025
• First Posted: February 6, 2025
• Study Start: October 24, 2023
• Primary Completion: March 11, 2024
• Study Completion: March 11, 2024
• Last Updated: February 6, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)